Stock Thread (27 Viewers)

[fantasycurse42]

So pissed I missed that sub-5

Missed my $4.90 by one cent the other day and 17 cents after falling $1.6 today. Unhappy about that!

 

[Charlie Harper]

Could it be that releasing the safety data was a simple task and releasing efficacy data requires more work?

Sure hope so. Still not selling. Was just as little worried, but realized NP has a big mouth.

 

[adonis]

Asks just getting eaten up. They tried and failed

Not a huge fail, price still down considerably.  We'll see how it ends up, but by now they could've covered on that latest run-up.  Odds are they made out ok.

 

[BassNBrew]

Sold my pre-market NRGU for a 9% profit

 

[BassNBrew]

Out of pre-market JWN for a 3% profit.

 

[Jayrok]

Not a huge fail, price still down considerably.  We'll see how it ends up, but by now they could've covered on that latest run-up.  Odds are they made out ok.

I hope some of them get greedy and take a huge loss by end of day.  

 

[fantasycurse42]

They’ll shake the weak hands early, that’s the time to add, IMO.

I mean come on! Did this nail it or what?

 

[fantasycurse42]

I mean come on! Did this nail it or what?

I’m just so ####### greedy I had to nickel and dime even though I knew what was coming

 

[Zegras11]

E ticket Day for sure here

 

[cosjobs]

I mean come on! Did this nail it or what?

Depends on whether you bought and how many

 

[BassNBrew]

SFY into the green.  Just placed a 1% trailing stop loss to lock in those profits for the day.

 

[fantasycurse42]

Depends on whether you bought and how many

I was gonna bump my $4.9 to $5... 

At the open, I was on the grill making some serious breakfast sammies for the fam, opened it we were $5.5 heading south quick and I thought $4.65 was going to be where it was bought.

Nonetheless, call was absolutely on point and I’m a greedy idiot!

 

[General Malaise]

Silver!  

 

[cosjobs]

I was gonna bump my $4.9 to $5... 

At the open, I was on the grill making some serious breakfast sammies for the fam, opened it we were $5.5 heading south quick and I thought $4.65 was going to be where it was bought.

Nonetheless, call was absolutely on point and I’m a greedy idiot!

I increased my position 12% on the downward slide. Avg. price about 5.44

 

[cosjobs]

Silver!  

Thanks for the ACQ mention yesterday. Wish I had bought more than 300

 

[cosjobs]

Silver!  

Also bought URA. Is there a better stock to play the evil rock?

 

[The Ref]

Damnit - went to a meeting and missed the drop

 

[JerseyToughGuys]

Silver!  

Breakout!

 

[General Malaise]

Also bought URA. Is there a better stock to play the evil rock?

SLV maybe? 

 

[General Malaise]

EVSI running like a scald dog! 

 

[The Ref]

Scary that they can dump shares like that and cause a $1.25 drop...... but the fact that it snap rebounded is a relief

 

[stbugs]

Damnit - went to a meeting and missed the drop

I don’t know how I could day trade without being retired. Some of this stuff moves so much during the day. I’m good with the shares I have. Not going to get greedy unless I see it fall later.

 

[adonis]

Scary that they can dump shares like that and cause a $1.25 drop...... but the fact that it snap rebounded is a relief

Still down 7% on a day where they release pretty good news for a drug that can be used to treat the worlds most pressing disease right now.  

 

[Jayrok]

Strong Safety Data in Mild to Moderate Smokes Gilead & Crushes Endpoint Leading to the First Potential Covid-19 Approval

Chart inside that shows Remdesivir vs Leronlimab for any adverse event.  

Leronlimab’s safety data shows a statistically significant reduction in SAEs of 32% between the active and placebo arm.  In most clinical trials a reduction of 30% or more represents an approvable endpoint. 

Hmm.  

 

[adonis]

I don’t know how I could day trade without being retired. Some of this stuff moves so much during the day. I’m good with the shares I have. Not going to get greedy unless I see it fall later.

Most of the movement happens, with CYDY, within the first 30 minutes of opening, and then in the last couple hours.  From what I hear, that's true of much of the market...first couple hours, and last couple hours generally.

 

[Jayrok]

Damnit - went to a meeting and missed the drop

Meetings... meetings are for quakers.  

 

[Big League Chew]

noob question... 

CYDY

im using ameritrade i have around 2k shares. i want to sell some but am unsure on when the funds will be 'cleared' so i can buy again?

last time i tried this i got a nasty email saying i cannot use uncleared funds more than a few times per X amount of months

 

[Zegras11]

Scary that they can dump shares like that and cause a $1.25 drop...... but the fact that it snap rebounded is a relief

6.75 to 5.07

 

[stbugs]

Still down 7% on a day where they release pretty good news for a drug that can be used to treat the worlds most pressing disease right now.  

Happens after running from $2.70 last week and being up 15-16% yesterday. While good news, not the full set of data so still risk.

 

[I-ROK]

Still down 7% on a day where they release pretty good news for a drug that can be used to treat the worlds most pressing disease right now.  

Can it? 
 

The release said the drug won’t harm you... that’s it

 

[The Ref]

6.75 to 5.07

Meh, Facts

NP don’t need them either 

 

[ghostguy123]

Still down 7% on a day where they release pretty good news for a drug that can be used to treat the worlds most pressing disease right now.  

Nobody knows about it, and the people who do already own a lot most likely.  

 

[fantasycurse42]

Can it? 
 

The release said the drug won’t harm you... that’s it

We’ve never seen you in here once, yet you were ready to rok at 6am, interesting.

GL, not a lot of weak hands in here.

 

[adonis]

Can it? 
 

The release said the drug won’t harm you... that’s it

That's not it.

It reduced the SAE's overall, and the SAE's that remained were said to not be related to leronlimab.

So not only does it not increase SAE's like remdesivir, it decreases them overall and doesn't add any on its own.

In order to decrease SAE's versus placebo, how do you think that happens without efficacy in reducing the severity of the disease?  The question is how efficacious is it, not whether it is or not.

 

[BassNBrew]

I'll be doing the same.  I suspect there will be a sharp pullback and choppy trading today.  I'm sure the shorts are primed to pounce.

sigh. I'm counting on the typical investor being a bit more skilled in interpreting these results.

I'm hoping there is weakness shown, as I would love to buy more. 

But I am afraid $8 will be the closest we see to weakness today

I think it open around 8. I think it goes beyond, but many variables besides the stock's value can impact that, including but not limited to: press reaction, short sellers, FED printing money and many others.

These result warrant a minimum of a 20% bump and as crazy positive as the market has been to positive COVID news it could go significantly higher.

I guess the typical investor wasn't more skilled.....

 

[CR69]

Can it? 
 

The release said the drug won’t harm you... that’s it

Which is what the results of the recent vaccines trials have said as well. 

 

[fantasycurse42]

That's not it.

It reduced the SAE's overall, and the SAE's that remained were said to not be related to leronlimab.

So not only does it not increase SAE's like remdesivir, it decreases them overall and doesn't add any on its own.

In order to decrease SAE's versus placebo, how do you think that happens without efficacy in reducing the severity of the disease?  The question is how efficacious is it, not whether it is or not.

We know there is a benefit, very likely substantial to the only approved treatment, this stuff takes time. I’m comfortable in my position.

 

[adonis]

The vast majority of days there's a drop after open and an increase later.  Most of the past 10 days it seems.

 

[BassNBrew]

That's not it.

It reduced the SAE's overall, and the SAE's that remained were said to not be related to leronlimab.

So not only does it not increase SAE's like remdesivir, it decreases them overall and doesn't add any on its own.

In order to decrease SAE's versus placebo, how do you think that happens without efficacy in reducing the severity of the disease?  The question is how efficacious is it, not whether it is or not.

IMO it's not a large enough sample size that the SAEs mean diddly.  The efficacy better be through the roof or we are looking at another trial that will take months to fill.  In the mean time big Pharma will get their treatments approved and we'll be talking about hope for cancer.

 

[fantasycurse42]

The Presidents tweet, accompanied by results this morning and the mention on his station yesterday are also of interest, IMO.

 

[adonis]

That's not it.

It reduced the SAE's overall, and the SAE's that remained were said to not be related to leronlimab.

So not only does it not increase SAE's like remdesivir, it decreases them overall and doesn't add any on its own.

In order to decrease SAE's versus placebo, how do you think that happens without efficacy in reducing the severity of the disease?  The question is how efficacious is it, not whether it is or not.

We know there is a benefit, very likely substantial to the only approved treatment, this stuff takes time. I’m comfortable in my position.

If it gets people out of the hospital faster than remdesivir, and it's safer, its' a home run.

 

[sporthenry]

Adam Feuerstein is a despicable human:

I think the lack of efficacy data is a fair criticism. My bigger issue is he seems to move the goalposts depending on who he is writing about. If it's about GILD, he'll pump it up on positive data from one hospital. Similar with MRNA, nobody put them under a microscope. 

 

[BassNBrew]

In the meantime....Blmn ran to $10.70 (I stop lossed at 10.54) and is not back down to 10.35 for those looking for an entry point.

 

[fantasycurse42]

I think the lack of efficacy data is a fair criticism. My bigger issue is he seems to move the goalposts depending on who he is writing about. If it's about GILD, he'll pump it up on positive data from one hospital. Similar with MRNA, nobody put them under a microscope. 

Yes, he’s a paid shill, we know this. His writings become meaningless over time. He’s gotta go find a new ticker where the strong hands aren’t as familiar with him.

 

[adonis]

IMO it's not a large enough sample size that the SAEs mean diddly.  The efficacy better be through the roof or we are looking at another trial that will take months to fill.  In the mean time big Pharma will get their treatments approved and we'll be talking about hope for cancer.

Not a large enough sample size based on what?  

If you set the experiments up correctly, you can get meaningful data with smaller populations.  This was a quality study and the results are quite good.  Statistical analysis will be used to determine what differences in population can be attributed to randomness, vs the effect of the drug.  

 

[cosjobs]

SLV maybe? 

for uranium?

 

[pmedina]

In the meantime....Blmn ran to $10.70 (I stop lossed at 10.54) and is not back down to 10.35 for those looking for an entry point.

In at 9.99 yesterday and out today at 10.60. Will rebuy at 10 . 

 

[BassNBrew]

In at 9.99 yesterday and out today at 10.60. Will rebuy at 10 . 

Well done and congrats.

I'm going to drip in in case $10 doesn't happen again.

 

[Polish Hammer]

Efficacy doesn't need to be through the roof, it needs to be statistically significant. If it comes in with a p-value of 0.01 or better, and with good safety, the medical community will love it. If it comes in say around 0.04 or so, that is still significant but will have a few looking for more data still. To me the way they are dripping out the info is not ideal, but they almost had to because of how they've been teasing results for so long (and occasionally missing some soft "deadlines" they set for themselves). I'd personally prefer they not release anything else until they have the analysis done on both the primary AND secondary endpoints. Then you can release it all at once and tell a complete story - good, bad, or mixed. 

That being said, I think that the interpretation that the SAEs are positive in their own right and hinting at efficacy is sound - but we can't know for sure until we see the rest of it. 

 

[Jayrok]

Efficacy doesn't need to be through the roof, it needs to be statistically significant. If it comes in with a p-value of 0.01 or better, and with good safety, the medical community will love it. If it comes in say around 0.04 or so, that is still significant but will have a few looking for more data still. To me they way they are dripping out the info is not ideal, but they almost had to because of how they've been teasing results for so long (and occasionally missing some soft "deadlines" they set for themselves). I'd personally prefer they not release anything else until they have the analysis done on both the primary AND secondary endpoints. Then you can release it all at once and tell a complete story - good, bad, or mixed. 

That being said, I think that the interpretation that the SAEs are positive in their own right and hinting at efficacy is sound - but we can't know for sure until we see the rest of it. 

Good posting.  Agree it would have been better if NP would have been able to release all endpoint data.  But anyone who knows or has (painfully) followed NP's interviews and PRs, understands he means well but sometimes can't keep his foot out of his mouth.  Consciously or not, he says things that are interpreted as promises and many end up not coming to fruition.  I think the safety data are good and does, in turn, hint to positive efficacy data.  But we'll have to wait and see.